Poolbeg Pharma PLC·Healthcare

Shares Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, were up 9% following the positive outcome of a...

Shares Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, were up 9% following the positive outcome of a pre-investigational new drug meeting with the US Food and Drug Administration (FDA) for lead asset POLB 001. Cavendish reiterated its 'buy' rating and 19p target price, noting the FDA discussions de-risk the overall development programme by ensuring that the regulator agrees, at least in principle, that the data produced through the clinical programme could support approval.

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has received positive feedback from the US Food and Drug Administration (FDA) in a pre-investigational new drug (IND) meeting for its lead asset POLB 001. POLB 001 is being developed as a potential preventative therapy for cytokine release syndrome (CRS), a serious side effect triggered by cancer immunotherapy treatments.

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has received a Canadian patent approval covering the use of its POLB 001 drug candidate in preventing cancer immunotherapy-induced cytokine release syndrome (CRS), a potentially life-threatening immune overreaction triggered by certain cancer treatments. The grant is the second national approval within Poolbeg's CRS patent family, following a ruling by IP Australia in March 2026.

Poolbeg Pharma PLC (POLBF) Q4 2025 Earnings Call Transcript

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, is heading into its most consequential period since flotation, as interim data from its lead drug candidate POLB 001 approaches and a second trial prepares to start. POLB 001 is designed as an oral preventative therapy for cytokine release syndrome (CRS), a potentially life-threatening inflammatory reaction that affects more than 70% of patients receiving CAR T-cell and bispecific antibody cancer treatments.
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
Healthcare
Biotechnology
15
2022-04-01
1.77